1278466-20-8

1278466-20-8 structure

Name: Lampalizumab
Chemical Name: Lampalizumab
CAS Number: 1278466-20-8
Molecular Formula:
Molecular Weight: 46.96 (kDa)
Catalog: Signaling Pathways Immunology/Inflammation Complement System
Create Date: 2023-01-25 08:52:38
Modify Date: 2024-01-21 21:20:39
Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research[1][2].

Name	Lampalizumab

Description	Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research[1][2].
Related Catalog	Signaling Pathways >> Immunology/Inflammation >> Complement System Research Areas >> Inflammation/Immunology
Target	Factor D[1]
In Vivo	Lampalizumab 经静脉注射给食蟹猴后，5小时内血清因子D水平增加近10倍，有效中和了其抑制活性[1]。
References	[1]. Yuan X, et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica. 2017 Mar;102(3):466-475. [2]. Hanus J, et al. Current therapeutic developments in atrophic age-related macular degeneration. Br J Ophthalmol. 2016 Jan;100(1):122-7.

Molecular Weight	46.96 (kDa)